{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T09:19:50Z","timestamp":1791623990290,"version":"4.3.4"},"reference-count":50,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,7,18]],"date-time":"2023-07-18T00:00:00Z","timestamp":1689638400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>We aimed to explore the predictive role of serum BDNF and anxiety-related variables in changes in somatic symptoms post-escitalopram treatment in panic disorder (PD) patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Ninety PD patients and 99 healthy controls (HCs) were enrolled. PD patients received an 8-week escitalopram treatment. All patients were administered the Panic Disorder Severity Scale\u2013Chinese Version (PDSS-CV) and State-Trait Anxiety Inventory (STAI) to assess panic and anxiety-related symptoms, respectively. Patient Health Questionnaire 15-item scale (PHQ-15) was performed to measure somatic symptoms, and the blood sample was collected to detect serum BDNF levels in all participants. We performed partial correlation analysis and multiple linear regression to explore correlates of PHQ-15 and predictors of PHQ-15 changes post-escitalopram treatment after controlling for age, gender, education levels (set as a dummy variable), the current duration, comorbid AP, and\/or GAD.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Compared to HCs, PD patients had lower serum BDNF levels and higher PHQ-15 scores that could be improved post-escitalopram treatment. Lower baseline STAI state (<jats:italic>b<\/jats:italic> = \u22120.07, <jats:italic>p<\/jats:italic> = 0.004), and PDSS-CV scores (<jats:italic>b<\/jats:italic> = \u22120.25, <jats:italic>p<\/jats:italic> = 0.007), but higher baseline serum BDNF levels (<jats:italic>b<\/jats:italic> = 0.35, <jats:italic>p<\/jats:italic> = 0.007) contributed to the prediction of PHQ-15 changes post-escitalopram treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>State anxiety, serum BDNF levels, and panic severity could predict changes in somatic symptoms post-escitalopram treatment, our results highlighted that serum BDNF could serve as a biological indicator for improving somatic symptoms in PD patients.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fpsyt.2023.1168771","type":"journal-article","created":{"date-parts":[[2023,7,18]],"date-time":"2023-07-18T08:07:07Z","timestamp":1689667627000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["Serum BDNF levels and state anxiety are associated with somatic symptoms in patients with panic disorder"],"prefix":"10.3389","volume":"14","author":[{"given":"Jiaxin","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ru","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dazhi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingguang","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,7,18]]},"reference":[{"key":"B1","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpsychores.2019.109815","article-title":"Identification and medical utilization of newly diagnosed panic disorder: a nationwide case-control study.","volume":"125","author":"Chang","year":"2019","journal-title":"J Psychosom Res."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1002\/da.22572","article-title":"Cross-national epidemiology of panic disorder and panic attacks in the world mental health surveys.","volume":"33","author":"de Jonge","year":"2016","journal-title":"Depress Anxiety."},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/srep28033","article-title":"Meta-analysis of the prevalence of anxiety disorders in mainland China from 2000 to 2015.","volume":"6","author":"Guo","year":"2016","journal-title":"Sci Rep."},{"key":"B4","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.jad.2016.07.015","article-title":"Meta-analysis of the efficacy of vortioxetine in patients with major depressive disorder (MDD) and high levels of anxiety symptoms.","volume":"206","author":"Baldwin","year":"2016","journal-title":"J Affect Disord."},{"key":"B5","doi-asserted-by":"publisher","first-page":"167","DOI":"10.4088\/pcc.v07n0405","article-title":"The importance of somatic symptoms in depression in primary care.","volume":"7","author":"Tylee","year":"2005","journal-title":"Prim Care Companion J Clin Psychiatry."},{"key":"B6","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1038\/npp.2016.146","article-title":"Inflammation in fear- and anxiety-based disorders: PTSD, GAD, and beyond.","volume":"42","author":"Michopoulos","year":"2017","journal-title":"Neuropsychopharmacology."},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1177\/2470547017736038","article-title":"The neurobiology of panic: a chronic stress disorder.","volume":"1","author":"Goddard","year":"2017","journal-title":"Chronic Stress."},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3390\/molecules26185657","article-title":"Cholecystokinin and panic disorder: reflections on the history and some unsolved questions.","volume":"26","author":"Rehfeld","year":"2021","journal-title":"Molecules."},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2019.00286","article-title":"Dysfunction in serotonergic and noradrenergic systems and somatic symptoms in psychiatric disorders.","volume":"10","author":"Liu","year":"2019","journal-title":"Front Psychiatry."},{"key":"B10","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1007\/s10571-017-0510-4","article-title":"BDNF: a key factor with multipotent impact on brain signaling and synaptic plasticity.","volume":"38","author":"Kowia\u0144ski","year":"2018","journal-title":"Cell Mol Neurobiol."},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/tp.2016.214","article-title":"The human BDNF gene: peripheral gene expression and protein levels as biomarkers for psychiatric disorders.","volume":"6","author":"Cattaneo","year":"2016","journal-title":"Transl Psychiatry."},{"key":"B12","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.psychres.2018.08.111","article-title":"The roles of brain-derived neurotrophic factor (BDNF) and glial cell line-derived neurotrophic factor (GDNF) in predicting treatment remission in a Chinese Han population with generalized anxiety disorder.","volume":"271","author":"Shen","year":"2019","journal-title":"Psychiatry Res."},{"key":"B13","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/j.jpsychires.2022.05.026","article-title":"Brain-derived neurotrophic factor as a biomarker for obsessive-compulsive disorder: a meta-analysis.","volume":"151","author":"Hao","year":"2022","journal-title":"J Psychiatr Res."},{"key":"B14","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.jad.2022.07.041","article-title":"Association between plasma levels of BDNF and GDNF and the diagnosis, treatment response in first-episode MDD.","volume":"315","author":"Liu","year":"2022","journal-title":"J Affect Disord."},{"key":"B15","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.jad.2023.01.107","article-title":"Serum BDNF levels are involved in the diagnosis and treatment response in patients with PD.","volume":"327","author":"Li","year":"2023","journal-title":"J Affect Disord."},{"key":"B16","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.psyneuen.2009.07.013","article-title":"Acute exercise ameliorates reduced brain-derived neurotrophic factor in patients with panic disorder.","volume":"35","author":"Str\u00f6hle","year":"2010","journal-title":"Psychoneuroendocrinology."},{"key":"B17","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1016\/j.pnpbp.2005.04.010","article-title":"Serum brain-derived neurotrophic factor (BDNF) levels in patients with panic disorder: as a biological predictor of response to group cognitive behavioral therapy.","volume":"29","author":"Kobayashi","year":"2005","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry."},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1111\/appy.12228","article-title":"Is the Val66met polymorphism of the brain-derived neurotrophic factor gene associated with panic disorder? A meta-analysis.","volume":"9","author":"Chen","year":"2017","journal-title":"Asia Pac Psychiatry."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1177\/0269881118788826","article-title":"Efficacy of vortioxetine on the physical symptoms of major depressive disorder.","volume":"32","author":"Christensen","year":"2018","journal-title":"J Psychopharmacol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.jad.2011.06.041","article-title":"Correlations between brain-derived neurotrophic factor and clinical symptoms in medicated patients with major depression.","volume":"135","author":"Satomura","year":"2011","journal-title":"J Affect Disord."},{"key":"B21","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1176\/appi.psy.47.4.348","article-title":"Somatic symptoms in outpatients with major depressive disorder treated with fluoxetine.","volume":"47","author":"Denninger","year":"2006","journal-title":"Psychosomatics."},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2021-066084","article-title":"Drug treatment for panic disorder with or without agoraphobia: systematic review and network meta-analysis of randomised controlled trials.","volume":"376","author":"Chawla","year":"2022","journal-title":"BMJ."},{"key":"B23","first-page":"292","article-title":"State-trait anxiety inventory and state-trait anger expression inventory.","author":"Spielberger","year":"1994","journal-title":"The Use of Psychological Testing for Treatment Planning and Outcome Assessment."},{"key":"B24","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1001\/archpsyc.61.9.913","article-title":"Somatic symptoms and physiologic responses in generalized anxiety disorder and panic disorder: an ambulatory monitor study.","volume":"61","author":"Hoehn-Saric","year":"2004","journal-title":"Arch Gen Psychiatry."},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2020.00466","article-title":"Panic disorder as unthinkable emotions: alexithymia in panic disorder, a croatian cross-sectional study.","volume":"11","author":"\u0160ago","year":"2020","journal-title":"Front Psychiatry."},{"key":"B26","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1080\/00016489.2018.1429652","article-title":"Psychiatric disorders in patients with intractable dizziness in the department of otolaryngology.","volume":"138","author":"Goto","year":"2018","journal-title":"Acta Otolaryngol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1007\/s40519-017-0367-z","article-title":"Symptoms of swallowing anxiety in panic disorder patients and associated psychopathologic factors.","volume":"23","author":"Budak","year":"2018","journal-title":"Eat Weight Disord."},{"key":"B28","first-page":"285","article-title":"Panic Disorder Severity Scale-Chinese Version: reliability and validity.","volume":"45","author":"Xiong","year":"2012","journal-title":"Chin J Psychiatry."},{"key":"B29","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1097\/00006842-200203000-00008","article-title":"The PHQ-15: validity of a new measure for evaluating the severity of somatic symptoms.","volume":"64","author":"Kroenke","year":"2002","journal-title":"Psychosom Med."},{"key":"B30","doi-asserted-by":"publisher","first-page":"44","DOI":"10.9758\/cpn.2012.10.1.44","article-title":"Long-term escitalopram treatment in korean patients with panic disorder: a prospective, naturalistic, open-label, multicenter trial.","volume":"10","author":"Choi","year":"2012","journal-title":"Clin Psychopharmacol Neurosci."},{"key":"B31","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpsychores.2020.110351","article-title":"Symptom-network dynamics in irritable bowel syndrome with comorbid panic disorder using electronic momentary assessment: a randomized controlled trial of escitalopram vs. placebo.","volume":"141","author":"Kreiter","year":"2021","journal-title":"J Psychosom Res."},{"key":"B32","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1016\/j.jad.2021.08.143","article-title":"Brain functional alterations in MDD patients with somatic symptoms: a resting-state fMRI study.","volume":"295","author":"Liu","year":"2021","journal-title":"J Affect Disord."},{"key":"B33","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1001\/archpsyc.60.2.170","article-title":"Family study of affective spectrum disorder.","volume":"60","author":"Hudson","year":"2003","journal-title":"Arch Gen Psychiatry."},{"key":"B34","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.jad.2015.09.060","article-title":"Panic disorder and agoraphobia: a direct comparison of their multivariate comorbidity patterns.","volume":"190","author":"Greene","year":"2016","journal-title":"J Affect Disord."},{"key":"B35","doi-asserted-by":"publisher","first-page":"107","DOI":"10.31887\/DCNS.2017.19.2\/macrocq","article-title":"The history of generalized anxiety disorder as a diagnostic category.","volume":"19","author":"Crocq","year":"2017","journal-title":"Dialog Clin Neurosci."},{"key":"B36","doi-asserted-by":"publisher","first-page":"535","DOI":"10.3109\/15622975.2011.587892","article-title":"Gender specific associations of serum levels of brain-derived neurotrophic factor in anxiety.","volume":"13","author":"Molendijk","year":"2012","journal-title":"World J Biol Psychiatry."},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3389\/fnint.2013.00055","article-title":"Brain-Derived Neurotrophic Factor (BDNF) Protein levels in anxiety disorders: systematic review and meta-regression analysis.","volume":"7","author":"Suliman","year":"2013","journal-title":"Front Integr Neurosci."},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10153377","article-title":"Effects of antidepressant treatment on neurotrophic factors (BDNF and IGF-1) in patients with major depressive disorder (MDD).","volume":"10","author":"Mosio\u0142ek","year":"2021","journal-title":"J Clin Med."},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1038\/tp.2013.30","article-title":"BDNF overexpression in mouse hippocampal astrocytes promotes local neurogenesis and elicits anxiolytic-like activities.","volume":"3","author":"Quesseveur","year":"2013","journal-title":"Transl Psychiatry."},{"key":"B40","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.psychres.2007.06.003","article-title":"The relation between anger management style, mood and somatic symptoms in anxiety disorders and somatoform disorders.","volume":"160","author":"Koh","year":"2008","journal-title":"Psychiatry Res."},{"key":"B41","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1080\/j.1440-1614.2006.01736.x","article-title":"Cognitive behavioural therapy for depression, panic disorder and generalized anxiety disorder: a meta-regression of factors that may predict outcome.","volume":"40","author":"Haby","year":"2006","journal-title":"Aust N Z J Psychiatry."},{"key":"B42","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1097\/NMD.0b013e3181b97d4d","article-title":"Predictors of clinical improvement in a randomized effectiveness trial for primary care patients with panic disorder.","volume":"197","author":"Chavira","year":"2009","journal-title":"J Nerv Ment Dis."},{"key":"B43","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/s0163-8343(02)00277-3","article-title":"Predictors of somatic symptoms in depressive disorder.","volume":"25","author":"Sayar","year":"2003","journal-title":"Gen Hosp Psychiatry."},{"key":"B44","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1111\/j.1469-7610.2009.02174.x","article-title":"Anxiety and depression are risk factors rather than consequences of functional somatic symptoms in a general population of adolescents: the TRAILS study.","volume":"51","author":"Janssens","year":"2010","journal-title":"J Child Psychol Psychiatry."},{"key":"B45","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.jad.2020.03.172","article-title":"Structural abnormalities in nucleus accumbens in patients with panic disorder.","volume":"271","author":"Yoshida","year":"2020","journal-title":"J Affect Disord."},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-020-02940-2","article-title":"A cross-sectional study of gastrointestinal symptoms, depressive symptoms and trait anxiety in young adults.","volume":"20","author":"S\u00f6derquist","year":"2020","journal-title":"BMC Psychiatry."},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/8811347","article-title":"Effect of a multistage educational skill-based program on nurse\u2019s stress and anxiety in the intensive care setting: a randomized controlled trial.","volume":"2021","author":"Saffari","year":"2021","journal-title":"Behav Neurol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1037\/pas0000155","article-title":"Factor structure and validity of the State-Trait Inventory for Cognitive and Somatic Anxiety.","volume":"28","author":"Roberts","year":"2016","journal-title":"Psychol Assess."},{"key":"B49","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1097\/nmd.0000000000001163","article-title":"Relationships between somatic symptoms and panic-agoraphobic spectrum among frequent attenders of the general practice in Italy.","volume":"208","author":"Carmassi","year":"2020","journal-title":"J Nerv Ment Dis."},{"key":"B50","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1080\/14740338.2018.1429403","article-title":"Risks and benefits of medications for panic disorder: a comparison of SSRIs and benzodiazepines.","volume":"17","author":"Quagliato","year":"2018","journal-title":"Expert Opin Drug Saf."}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2023.1168771\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,18]],"date-time":"2023-07-18T08:07:14Z","timestamp":1689667634000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2023.1168771\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,18]]},"references-count":50,"alternative-id":["10.3389\/fpsyt.2023.1168771"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2023.1168771","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,18]]},"article-number":"1168771"}}